Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Madrigal Pharmaceuticals ( (MDGL) ) just unveiled an update.
On July 17, 2025, Madrigal Pharmaceuticals entered into a $500 million senior secured credit facility with funds managed by Blue Owl Capital to advance its MASH pipeline and refinance existing debt. The financing includes a $350 million initial term loan and a $150 million delayed draw term loan facility, with an option for additional incremental facilities of up to $250 million. This agreement aims to strengthen Madrigal’s capital position and extend its leadership in the MASH treatment market, supported by the strong U.S. launch momentum of Rezdiffra and ongoing clinical trials.
The most recent analyst rating on (MDGL) stock is a Buy with a $390.00 price target. To see the full list of analyst forecasts on Madrigal Pharmaceuticals stock, see the MDGL Stock Forecast page.
Spark’s Take on MDGL Stock
According to Spark, TipRanks’ AI Analyst, MDGL is a Neutral.
Madrigal Pharmaceuticals presents a mixed investment case. Strong revenue growth and a successful product launch boost its appeal, but profitability remains a challenge due to high operational costs. The stable balance sheet offers some reassurance, though ongoing cash burn and external financing reliance are risks. Technical indicators suggest a neutral stance with potential for growth, while the valuation reflects the high-risk nature typical of biotech firms.
To see Spark’s full report on MDGL stock, click here.
More about Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Their medication, Rezdiffra, is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH.
Average Trading Volume: 335,055
Technical Sentiment Signal: Strong Buy
Current Market Cap: $7.42B
Learn more about MDGL stock on TipRanks’ Stock Analysis page.